PMID- 34250840
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20221207
IS  - 2058-7384 (Electronic)
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 35
DP  - 2021 Jan-Dec
TI  - Different dose of new generation proton pump inhibitors for the treatment of 
      Helicobacter pylori infection: A meta-analysis.
PG  - 20587384211030397
LID - 10.1177/20587384211030397 [doi]
LID - 20587384211030397
AB  - The evidence on whether high-dose new generation proton pump inhibitors (PPIs) 
      including rabeprazole and esomeprazole achieve a higher eradication rate of 
      Helicobacter pylori has not been assessed. The primary comparison was eradication 
      and adverse events (AEs) rate of standard (esomeprazole 20 mg bid, rabeprazole 
      10 mg bid) versus high-dose (esomeprazole 40 mg bid, rabeprazole 20 mg bid) PPIs. 
      Sub-analyses were performed to evaluate the eradication rate between Asians and 
      Caucasians, clarithromycin-resistance (CAM-R) strains, and 
      clarithromycin-sensitivity (CAM-S) strains of different dose PPIs. We conducted a 
      literature search for randomized controlled trials comparing high-with 
      standard-dose esomeprazole and rabeprazole for H. pylori eradication and AEs. A 
      total of 12 trials with 2237 patients were included. The eradication rate of 
      high-dose PPIs was not significantly superior to standard-dose PPIs regimens: 
      85.3% versus 84.2%, OR 1.09 (0.86-1.37), P = 0.47. The high dose induced more AEs 
      than those of the standard dose, but didn't reach statistical significance (OR 
      1.25, 95% CI: 0.99-1.56, P = 0.06). Subgroup analysis showed that the difference 
      in eradication rate of PPIs between high- and standard-dose groups were not 
      statistically significant both in Asians (OR 0.99, 95% CI 0.75-1.32, P = 0.97) 
      and Caucasians (OR 1.27, 95% CI 0.84-1.92, P = 0.26). Furthermore, there were 
      similar eradication rates in CAM-S (OR 1.2; 95% CI 0.58-2.5; P = 0.63) and CAM-R 
      strains (OR 1.08; 95% CI 0.45-2.56; P = 0.87) between the standard-and high-dose 
      groups. High and standard dosages of new generation of the PPIs showed similar H. 
      pylori eradication rates and AEs as well as between Asian versus Caucasian 
      populations, with or without clarithromycin-resistance. However, further studies 
      are needed to confirm.
FAU - Gao, Wenwen
AU  - Gao W
AUID- ORCID: 0000-0002-6176-8668
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, Shandong, China.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, Shandong, China.
FAU - Yin, Yanhui
AU  - Yin Y
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, Shandong, China.
FAU - Yu, Shuwen
AU  - Yu S
AD  - Department of Pharmacy, Qilu Hospital of Shandong University, Jinan, Shandong, 
      China.
AD  - Phase I Clinical Trial Center, Qilu Hospital of Shandong University, Jinan, 
      Shandong, China.
AD  - NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, 
      Shandong University, Jinan, Shandong, China.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical 
      University, Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - Asian People
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance, Microbial/drug effects
MH  - Esomeprazole/therapeutic use
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - *Helicobacter pylori
MH  - Humans
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects/*therapeutic use
MH  - Rabeprazole/therapeutic use
MH  - White People
PMC - PMC8274125
OTO - NOTNLM
OT  - Clarithromycin resistance
OT  - Helicobacter pylori
OT  - different dose
OT  - esomeprazole
OT  - ethnic difference
OT  - meta-analysis
OT  - new generation proton pump inhibitors
OT  - rabeprazole
COIS- Declaration of conflicting interests: No conflict of interest exits in the 
      submission of this manuscript "Different dose of new generation proton pump 
      inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis," 
      and manuscript is approved by all authors for publication. I would like to 
      declare on behalf of my co-authors that the work described was original research 
      that has not been published previously, and not under consideration for 
      publication elsewhere, in whole or in part. All the authors listed have approved 
      the manuscript that is enclosed.
EDAT- 2021/07/13 06:00
MHDA- 2022/01/11 06:00
PMCR- 2021/07/10
CRDT- 2021/07/12 08:42
PHST- 2021/07/12 08:42 [entrez]
PHST- 2021/07/13 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/07/10 00:00 [pmc-release]
AID - 10.1177_20587384211030397 [pii]
AID - 10.1177/20587384211030397 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211030397. doi: 
      10.1177/20587384211030397.